Are pharmacological considerations of relevance in hormone replacement therapy for prevention of chronic disease?

References

• Adams M.R., Register T.C., Golden D.L., Wagner J.D. and Williams J.K. (1997) Medroxyprogesterone acetate anta-gonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology, 17,217–221.
   Google Scholar
• Chen Y., Liu X., Pisha E., Constantinou Al., Hua Y., Shen L., van Breemen R.B., Elguindi E.C., Blond S.Y., Zhang F. and Bolton J.L. (2000) A metabolite of equine estrogens, 4-hydroxyequilenin induces DNA damage and apoptosis in breast cancer cell lines. Chemical Research in Toxicology, 13, 342–350.
   Google Scholar
• Cline J.M., Soderqvist G., von Schoultz E., Skoog L. and von Schoultz B. (1996) Effects of hormone replacement therapy on mammary gland of surgically postmenopausal cyno-molgus macaques. American Journal of Obstetrics and Gynecology, 174, 93–100.
   Google Scholar
• Cline J.M., Soderqvist G., von Schoultz E., Skoog L. and von Schoultz B. (1998) Effects of conjugated estrogens, medroxy-progesterone and tamoxifen on the mammary glands of macaques. Breast Cancer Research and Treatment, 48, 221–229.
   Google Scholar
• Colditz G.A. and Rosner B. (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. American Journal of Epidemiology, 152, 950–964.
   PubMed Web of Science ®Google Scholar
• Dey M. (1999) The new science of hormone replacement therapy. Journal of the Birtish Menopause Society, Supplement S2, 4–5.
   Google Scholar
• Enserink M. (2002) Women's health. The vanishing promises of hormone replacement. Science, 297, 325–326.
   PubMed Web of Science ®Google Scholar
• Fletcher S.W. and Colditz G.A. (2002) Failure of estrogen plus progestin therapy for prevention. Journal of the American Medical Association, 288, 366–368.
   Google Scholar
• Godsland I.F. (1998) Effects on carbohydrate metabolism. In: Estrogens and Progestogens in Clinical Practice, edited by Fraser IS., Jansen R.P.S., Lobo R.A. and Whitehead MI., pp. 773–785. London: Churchill Livingstone.
   Google Scholar
• Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., Hsia J., Hulley S., Herd A., Khan S., Newby L.K., Waters D., Vittinghoff E. and Wenger N. (2002) Cardiovascular disease outcomes during 6.8 years of hormone replacement therapy. Journal of the American Medical Association, 288, 49–57.
   PubMed Web of Science ®Google Scholar
• Haarbo J., Leth-Espensen P., Stender S. and Christiansen C. (1991) Estrogen monotherapy and combined estrogen—progestogen replacement therapy attenuate aortic accumula-tion of cholesterol in ovariectomized cholesterol-fed rabbits. Journal of Clinical Investigation, 87, 1274–1279.
   PubMed Web of Science ®Google Scholar
• Hofseth L.J., Raafat A.M., Osuch J.R., Pathak DR., Slomski C.A. and Haslam S.Z. (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. Journal of Clinical Endocrinology and Metabolism, 84, 4559–4565.
   PubMed Web of Science ®Google Scholar
• Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. and Vittinghoff E. (1998) Randomized trial for estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association, 280, 605–613.
   PubMed Web of Science ®Google Scholar
• Klein R. (1998) The composition of premarin. International Journal of Fertility, 43, 223.
   Google Scholar
• Lane G., Siddle N., Ryder TA., Pryse-Davies J., King R.J.B. and Whitehead M.I. (1986) Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy? Fertility and Sterility, 45, 345–352.
   Google Scholar
• Lippert T.H., Seeger H. and Mueck A.O. (2000a) The impact of endogenous estradiol metabolites on carcinogenesis. Steroids, 65, 357–369.
   PubMed Web of Science ®Google Scholar
• Lippert T.H., Mueck A.O. and Seeger H. (2000b) Is the use of conjugated equine estrogens in hormone replacement therapy still appropriate? British Journal of Clinical Pharmacology, 49, 489–490.
   Google Scholar
• Lippert T.H., Seeger H. and Mueck A.O. (2001) Pharmacology and toxicology of different estrogens. Gynecological Endocrinology, 15 (Suppl. 4), 26–33.
   Google Scholar
• Liu X., Yao J., Pisha E., Yang Y., Hua Y., van Breemen R.B. and Bolton J.L. (2002) Oxidative DNA damage induced by equine estrogen metabolites: role of estrogen receptor alpha. Chemical Research in Toxicology, 15, 512–519.
   PubMed Web of Science ®Google Scholar
• Lobo R.A., Kelsey J. and Marcus R. (2000) Menopause, Biology and Pathobiology. San Diego, Academic Press.
   Google Scholar
• MacLennan A.H., MacLennan A., Wenzel S., Chambers H.M. and Eckert K. (1993) Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Medical Journal of Australia, 159, 102–106.
   PubMed Web of Science ®Google Scholar
• Parfitt K. (1999) Martindale, The complete Drug Reference, 32nd edition, pp. 1457–1458. London, Pharmaceutuical press.
   Google Scholar
• Ross R.K., Paganini-Hill A., Wan P.C. and Pike M.C. (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute, 92, 328–332.
   Google Scholar
• Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L. and Hoover R. (2000) Menopausal estrogen and estrogen— progestin replacement therapy and breast cancer risk. Journal of the American Medical Association, 283, 485–491.
   Google Scholar
• Williams J.K., Honore E.K., Washburn S.A. and Clarkson T.B. (1994) Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. Journal of the American College of Cardiology, 24, 1757–1761.
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Invetigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. Journal of the American Medical Association, 288, 312–333.
   Google Scholar